CTLA4 and lung carcinoma: At present, both PD-1/PD-L1 and CTLA-4 blockades have been approved for the treatment of lung cancer; however, the limited efficacy and immune-related adverse events of ICIs, led to the discovery of novel checkpoints molecules.